• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Top 10 Drug Delivery Technologies (2010 - 2015) - Product Image

Top 10 Drug Delivery Technologies (2010 - 2015)

  • Published: February 2011
  • Region: Global
  • 264 Pages
  • Markets and Markets

STUDY GOALS AND OBJECTIVES:

- To define and measure drug delivery market and its various sub-segments with respect to types of systems, by mode of drug delivery, by therapeutics and others.

- To identify major drivers and restraints of the market

- To evaluate comprehensively all drug delivery technologies and benchmark them against various parameters to identify top ten technologies.

- To identify and analyze comprehensively market structure with respect to the factors influencing market growth and industry specific challenges.

- To analyze trends and forecasts of drug delivery market and its segments

- To identify major stakeholders in the market and draw a competitive landscape for market leaders for each of the drug delivery technology market.

- To analyze opportunities in the market for stakeholders

- To strategically analyze micro markets with respect to their individual growth trends, future prospects and contribution to the total market

- To understand regulatory framework, design criteria, pricing issues, threat from alternative methods available in the market.

- To analyze and forecast revenues READ MORE >

Executive Summary
Objective
Market Scenario
Emerging Technologies

1 Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology

2 Summary

3 Market Overview
3.1 Introduction
3.2 Role Of Drug Delivery In Drug Life Cycle
3.3 Stakeholders
3.4 Challenges
3.4.1 Government Regulations
3.4.2 Pricing Pressure, Reimbursements, & Third-Party Dependence
3.4.3 Patent Litigations
3.4.4 Pharma Companies Develop In-House Drug Delivery Capabilities
3.5 Convenience Is The Key For Commercial Success Of Future Drugs
3.6 Patent Analysis

4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Patent Expiration Of Drugs
4.2.2 Need For Effective Delivery Of Novel Pharmaceuticals & Biopharmaceuticals
4.2.3 Reduce Attrition Rates & Faster Drug Discovery/Development Processes
4.2.4 Expanded Applications Of Unconventional Modes Of Drug Delivery
4.2.5 Innovations In Drug Delivery Technologies
4.3 Restraints
4.3.1 Drug Failures Raise Concerns On Roi
4.3.2 U.S. Healthcare Reforms
4.4 Opportunities
4.4.1 Home-Care Drug Delivery Devices & Self-Administration
4.4.2 Niche Therapeutic Areas
4.4.3 Wellness Products

5 Controlled Release Technology
5.1 Introduction
5.1.1 Key Market Players
5.2 Drivers
5.2.1 Controlled Release Formulations In Key Therapeutic Areas
5.2.2 Once-A-Day Formulations
5.2.3 Cost Effective
5.3 Restraints
5.3.1 Limited Number Of Materials
5.3.2 Technical Barriers
5.4 Opportunities
5.4.1 Particulate & Chronopharmacokinetic Systems
5.4.2 Mucoadhesive Drug Delivery
5.5 Biodegradable Polymers
5.6 Hydrogel
5.7 Multiparticulate Bead Systems
5.8 Ion Exchange Resins
5.9 Osmotic Pressure Controlled Systems
5.10 Dissolution/Diffusion Systems
5.10.1 Matrix Systems
5.10.2 Reservoir Systems
5.11 Others
5.12 Regulatory Environment
5.13 Controlled Release Vs Immediate Release Formulations
5.14 Innovations In Controlled Release Technologies
5.15 Burning Issues
5.16 Winning Imperatives
5.17 Competitive Developments

6 Targeted Delivery
6.1 Introduction
6.1.1 Key Market Players
6.2 Drivers & Restraints
6.2.1 Increased Demand For Treatment Of Cancerous Tumors
6.2.2 Lack Of Targeted Drug Delivery Technologies For Treatment Of Brain Tumor
6.2.3 High Cost Of Targeted Antibody-Based Cancer Therapeutics
6.3 Opportunity
6.3.1 Novel Targeted Drug Delivery Systems
6.4 Targeting Ligands
6.4.1.1 Antibody Fragment Drug Conjugate Delivery
6.4.1.2 Antibody Directed Enzyme Prodrug Targeted Delivery
6.4.1.3 Peptide-Targeted Delivery
6.4.1.4 Small Molecule Conjugate Delivery
6.4.1.5 Others
6.5 Non-Biological Targeting Platforms
6.6 Currently Marketed Targeted Therapies
6.7 Impact Of Targeted Drug Delivery In Cancer & Other Chronic Conditions
6.8 Innovations
6.9 Industry Insights
6.10 Winning Imperatives

7 Encapsulation Technologies
7.1 Introduction
7.1.1 Key Market Players
7.2 Drivers & Restraints
7.2.1 Enhanced Bioavailability
7.2.2 Extensive Usage In Taste Masking & Faster Dissolving Pills
7.2.3 Economically Feasible
7.2.4 Reluctance In Investing In Novel Technologies
7.3 Opportunity
7.3.1 Sophisticated Microencapsulation Systems
7.4 Taste Masking
7.5 Fast Dissolving Pills
7.6 Evolution Of Encapsulation Technologies
7.7 Application Of Encapsulation Technologies In Different Modes Of Drug Delivery
7.8 Industry Insights
7.9 Winning Imperatives
7.10 Competitive Developments

8 Topical Formulations
8.1 Introduction
8.1.1 Key Market Players
8.2 Drivers & Restraints
8.2.1 Burn & Wound Treatment
8.2.2 Bypassing First Pass Effect
8.2.3 Convenience Factor
8.2.4 Usage In Limited Therapeutic Areas
8.3 Opportunity
8.3.1 Technology Advancements Expand Applications
8.4 Gel Technology
8.5 Microemulsions
8.6 Biphasic System
8.7 Others
8.8 Industry Insights
8.9 Winning Imperatives
8.10 Competitive Developments

9 Inhaler Technology
9.1 Introduction
9.1.1 Key Market Players
9.2 Drivers & Restraints
9.2.1 Increase In Asthma & Copd Patients
9.2.2 Technological Advancements In Aerosol Formulation And Device Design
9.2.3 Ease Of Use, Self-Administration, & Painless Drug Delivery
9.2.4 Failure Of Exubera
9.3 Opportunity
9.3.1 Application In Non-Respiratory Conditions
9.4 Dry Powder Inhalers
9.5 Metered Dose Inhalers
9.6 Nebulizers
9.7 Evolution Of Inhaler Devices
9.8 Regulatory Environment
9.9 Technology Innovations
9.10 Industry Insights
9.11 Winning Imperatives
9.12 Competitive Developments

10 Injectable Drug Delivery
10.1 Injection Devices
10.1.1 Key Market Dynamics
10.1.1.1 Drivers
10.1.1.1.1 Growth Of Self-Administration Therapies
10.1.1.1.2 Needle-Stick Legislation
10.1.1.1.3 Increasing Acceptance By Physicians And Patients
10.1.1.1.4 Reducing Cost Of Treatment
10.1.1.2 Restraints
10.1.1.2.1 Need Of New Drug Formulation
10.1.1.3 Opportunities
10.1.1.3.1 Product Differentiation Through Added Functional Features
10.1.1.3.2 Expansion To New Areas
10.2 Criteria For Selection Of Injectable Device
10.3 Key Developments
10.3.1 Development Of Microneedles
10.3.2 Development Of Needle-Free Devices For Administration Of Powdered Drugs
10.4 Conventional Injectables
10.5 Prefilled Syringes (Pfs)
10.5.1 Key Market Dynamics
10.5.1.1 Drivers
10.5.1.1.1 Growing Market For Self-Injection Devices
10.5.1.1.2 Wastage Control And Cost Reduction Through Less Overfill
10.5.1.1.3 Ease Of Manufacture & Convenient Usability
10.5.1.2 Restraints
10.5.1.2.1 Threat From Needle-Free Devices
10.5.1.2.2 Protecting Product Quality
10.5.2 Glass Pfs
10.5.3 Plastic Pfs
10.6 Self Injection Devices
10.6.1 Auto Injectors
10.6.1.1 Reusable Auto-Injectors
10.6.1.2 Disposable Auto-Injectors
10.6.2 Pen Injectors
10.6.2.1 Reusable Pen Injectors
10.6.2.2 Disposable Pen Injectors
10.6.3 Needle-Free Injectors (Nfi)
10.6.3.1 Reusable Nfis
10.6.3.2 Disposable Nfis
10.7 Others

11 Transdermal Patch
11.1 Introduction
11.1.1 Key Market Players
11.2 Drivers
11.2.1 Reduced Side Effects & Better Efficacy
11.2.2 Convenient & Less Painful
11.3 Restraints
11.3.1 Recall Of Duragesic & Negative Publicity Of Ortho Evra Patch
11.3.2 Low Skin Permeability Of Drugs
11.4 Opportunities
11.4.1 New Products
11.4.1.1 Contraceptive Patch
11.4.1.2 Pain Management Patch
11.4.1.3 Estrogen/Hormone Replacement Patch
11.5 Industry Insights
11.6 Winning Imperatives
11.7 Competitive Developments

12 Implantable Drug Delivery
12.1 Introduction
12.2 Drivers & Restraints
12.2.1 Selective Drug Delivery & Low Amount Of Active Drug Ingredient
12.2.2 Dosing Administration Not Required
12.2.3 Inconvenience
12.3 Opportunity
12.3.1 Technological Advances Enhance Applications
12.4 Coronary (Drug Eluting) Stents
12.5 Implantable Infusion Pumps
12.6 Ocular Implants & Others
12.7 Industry Insights
12.8 Winning Imperatives

13 Liposomal Drug Delivery
13.1 Introduction
13.2 Drivers & Restraints
13.2.1 Enhanced Usage In Cancer
13.2.2 Easy Manufacturing Procedure & Cost Effectiveness
13.2.3 Side Effects
13.3 Opportunity
13.3.1 Nanoscale Liposome Drug Delivery
13.4 Industry Insights
13.5 Winning Imperatives
13.6 Competitive Developments

14 Pegylation Technologies
14.1 Introduction
14.2 Drivers & Restraints
14.2.1 Biological Drugs
14.2.2 Enhanced Pharmacokinetic Properties & Reduced Dosage
14.2.3 Expensive Manufacturing Procedure
14.3 Opportunity
14.3.1 Technological Advances
14.4 Industry Insights
14.5 Winning Imperatives

15 Competitive Landscape
15.1 Introduction
15.2 Analysis Of Top Players
15.2.1 Strategy
15.2.2 Injectable Drug Delivery Devices Market Share
15.2.2.1 Top Injectable Drug Delivery Device Companies & Revenues, By Segment
15.3 Winning Imperatives
15.3.1 Alliances
15.3.2 Positioning Of Drug Delivery Technology Early In Drug Discovery
15.3.3 Shift From Pure Drug Delivery Toward Specialty Pharmaceuticals
15.4 Strategic Recommendations

16 Geographic Analysis
16.1 Introduction
16.2 North America
16.3 Europe
16.4 Asia
16.5 Rest Of The World (Row)
16.6 Decision Support Database

17 Company Profiles
17.1 3M Company
17.1.1 Overview
17.1.2 Financials
17.1.3 Products & Services
17.1.4 Strategy
17.1.5 Developments
17.2 Alkermes, Inc
17.2.1 Overview
17.2.2 Financials
17.2.3 Products & Services
17.2.4 Strategy
17.2.5 Developments
17.3 Altea Therapeutics Inc.
17.3.1 Overview
17.3.2 Products & Services
17.3.3 Strategy
17.3.4 Developments
17.4 Antares Pharma Inc.
17.4.1 Overview
17.4.2 Financials
17.4.3 Products & Services
17.4.4 Strategy
17.4.5 Developments
17.5 A.P. Pharma, Inc.
17.5.1 Overview
17.5.2 Financials
17.5.3 Products & Services
17.5.4 Strategy
17.5.5 Developments
17.6 Applied Pharma
17.6.1 Overview
17.6.2 Products & Services
17.6.3 Strategy
17.6.4 Developments
17.7 Aradigm Corporation
17.7.1 Overview
17.7.2 Financials
17.7.3 Products & Services
17.7.4 Strategy
17.7.5 Developments
17.8 Baxter Biopharma
17.8.1 Overview
17.8.2 Products & Services
17.8.3 Financials
17.8.4 Strategy
17.8.5 Develop0Ments
17.9 Becton, Dickinson And Company
17.9.1 Overview
17.9.2 Product & Services
17.9.3 Financials
17.9.4 Strategy
17.9.5 Developments
17.10 Bioject Inc.
17.10.1 Overview
17.10.2 Financials
17.10.3 Products & Services
17.10.4 Strategy
17.10.5 Developments
17.11 Biovail Corporation (Valeant Pharmaceuticals International Inc.)
17.11.1 Overview
17.11.2 Products & Services
17.11.3 Financials
17.11.4 Strategy
17.11.5 Developments
17.12 Cima Labs Inc.
17.12.1 Overview
17.12.2 Products & Services
17.12.3 Strategy
17.12.4 Developments
17.13 Elan Corporation Plc.
17.13.1 Overview
17.13.2 Financials
17.13.3 Products & Services
17.13.4 Strategy
17.13.5 Developments
17.14 Endo Pharmaceuticals
17.14.1 Overview
17.14.2 Financials
17.14.3 Products & Services
17.14.4 Strategy
17.14.5 Developments
17.15 Eurand Pharmaceuticals
17.15.1 Overview
17.15.2 Financials
17.15.3 Products & Services
17.15.4 Strategy
17.15.5 Developments
17.16 Flamel Technologies, Inc
17.16.1 Overview
17.16.2 Financials
17.16.3 Products & Services
17.16.4 Strategy
17.16.5 Developments
17.17 Johnson & Johnson Ltd.
17.17.1 Overview
17.17.2 Financials
17.17.3 Products & Services
17.17.4 Strategy
17.17.5 Developments
17.18 Kv Pharmaceutical
17.18.1 Overview
17.18.2 Financials
17.18.3 Products & Services
17.18.4 Strategy
17.18.5 Developments
17.19 Labopharm Inc.
17.19.1 Overview
17.19.2 Financials
17.19.3 Products & Services
17.19.4 Strategy
17.19.5 Developments
17.20 Nanopass Technologies Ltd.
17.20.1 Overview
17.20.2 Products & Services
17.20.3 Strategy
17.20.4 Developments
17.21 Nektar Therapeutics
17.21.1 Overview
17.21.2 Financials
17.21.3 Products & Services
17.21.4 Strategy
17.21.5 Developments
17.22 Qlt Inc.
17.22.1 Overview
17.22.2 Financials
17.22.3 Products & Services
17.22.4 Strategy
17.22.5 Developments
17.23 Skyepharma Plc.
17.23.1 Overview
17.23.2 Financials
17.23.3 Products & Services
17.23.4 Strategy
17.23.5 Developments
17.24 Surmodics, Inc.
17.24.1 Overview
17.24.2 Products & Services
17.24.3 Financials
17.24.4 Strategy
17.24.5 Developments
17.25 Vectura Group Plc
17.25.1 Overview
17.25.2 Financials
17.25.3 Products & Services
17.25.4 Strategy
17.25.5 Developments
17.26 Ypsomed Holding Ag
17.26.1 Overview
17.26.2 Financials
17.26.3 Products & Services
17.26.4 Strategy
17.26.5 Developments
17.27 Zogenix, Inc.
17.27.1 Overview
17.27.2 Products & Services
17.27.3 Strategy
17.27.4 Develop0Ments

Appendix
U.S. Patents
Europe Patents
Japan Patents

List Of Tables

Table 1 Top 10 Drug Delivery Technologies Market, By Segments, 2008 – 2015 ($Million)
Table 2 Drugs Set For Patent Expiration, 2010 – 2012
Table 3 Impact Analysis Of Key Market Dynamics
Table 4 Global Controlled Release Technology Market, By Products, 2008 – 2015 ($Million)
Table 5 Global Controlled Release Technology Market, By Geography, 2008 – 2015 ($Million)
Table 6 Impact Analysis Of Key Market Dynamics
Table 7 Global Biodegradable Polymers Market, By Geography, 2008 – 2015 ($Million)
Table 8 Global Hydrogel Market, By Geography 2008 – 2015 ($Million)
Table 9 Global Multiparticulate Bead Systems Market, By Geography, 2008 – 2015 ($Million)
Table 10 Global Ion Exchange Resins Market, By Geography, 2008 – 2015 ($Million)
Table 11 Global Osmotic Pressure Controlled Systems Market, By Geography, 2008 – 2015 ($Million)
Table 12 Global Dissolution/Diffusion Systems Market, By Geography, 2008 – 2015 ($Million)
Table 13 Global Matrix Systems Market, By Geography, 2008 – 2015 ($Million)
Table 14 Global Reservoir Systems Market, By Geography, 2008 – 2015 ($Million)
Table 15 Global Other Controlled Release Systems Market, By Geography, 2008 – 2015 ($Million)
Table 16 Global Targeted Delivery Technology Market, By Products, 2008 – 2015 ($Million)
Table 17 Global Targeted Delivery Market, By Geography, 2008 – 2015 ($Million)
Table 18 Impact Analysis Of Key Market Dynamics
Table 19 Global Targeting Ligands Market, By Products, 2008 – 2015 ($Million)
Table 20 Global Targeting Ligands Market, By Products, 2008 – 2015 ($Million)
Table 21 Global Antibody Fragment Conjugate Delivery Market, By Geography, 2008 – 2015 ($Million)
Table 22 Global Antibody Enzyme Directed Prodrug Delivery Market, By Geography, 2008 – 2015 ($Million)
Table 23 Global Peptide Targeted Drug Delivery Market, By Geography, 2008 – 2015 ($Million)
Table 24 Global Small Molecule Conjugate Delivery Market, By Geography, 2008 – 2015 ($Million)
Table 25 Global Other Targeting Ligands Based Delivery Market, By Geography, 2008 – 2015 ($Million)
Table 26 Global Non-Biological Targeting Platforms Market, By Geography, 2008 – 2015 ($Million)
Table 27 Global Encapsulation Technology Market, By Products, 2008 – 2015 ($Million)
Table 28 Global Encapsulation Technologies Market, By Geography, 2008 – 2015 ($Million)
Table 29 Impact Analysis Of Key Market Dynamics
Table 30 Global Encapsulation Market In Taste Masking, By Geography, 2008 – 2015 ($Million)
Table 31 Global Encapsulation Market In Fast Dissolving, By Geography, 2008 – 2015 ($Million)
Table 32 Global Topical Formulations Market, By Products, 2008 – 2015 ($Million)
Table 33 Global Topical Formulations Market, By Geography, 2008 – 2015
Table 34 Impact Analysis Of Key Market Dynamics
Table 35 Global Gel Technology Market, By Geography, 2008 – 2015 ($Million)
Table 36 Global Microemulsions Market, By Geography, 2008 – 2015 ($Million)
Table 37 Global Biphasic Systems Market, By Geography, 2008 – 2015 ($Million)
Table 38 Global Other Topical Formulations Market, By Geography, 2008 – 2015 ($Million)
Table 39 Global Inhaler Technology Market, By Products, 2008 – 2015 ($Million)
Table 40 Global Inhaler Technology Market, By Geography, 2008 – 2015 ($Million)
Table 41 Impact Analysis Of Key Market Dynamics
Table 42 Global Dry Powder Inhalers Market, By Geography, 2008 – 2015 ($Million)
Table 43 Global Metered Dose Inhalers Market, By Geography, 2008 – 2015 ($Million)
Table 44 Global Nebulizers Market, By Geography, 2008 – 2015 ($Million)
Table 45 Global Injectable Drug Delivery Devices Market, By Products, 2008 – 2015 ($Million)
Table 46 Global Injectable Drug Delivery Devices Market, By Geography, 2008-2015 ($Million)
Table 47 Impact Analysis Of Key Market Dynamics
Table 48 Global Conventional Injection Devices Market, By Geography, 2008 – 2015 ($Million)
Table 49 Global Prefilled Syringes Market, By Products, 2008 – 2015 ($Million)
Table 50 Global Prefilled Syringes Market, By Geography, 2008 – 2015 ($Million)
Table 51 Global Self-Injection Devices Market, By Products, 2008 – 2015 ($Million)
Table 52 Global Self-Injection Devices Market, By Geography, 2008 – 2015 ($Million)
Table 53 Global Auto Injector Market, By Products, 2008 – 2015 ($Million)
Table 54 Global Auto Injector Market, By Geography, 2008 – 2015 ($Million)
Table 55 Global Pen Injector Market, By Products, 2008 – 2015 ($Million)
Table 56 Global Pen Injector Market, By Geography, 2008 – 2015 ($Million)
Table 57 Major Products In The Needle Free Technology
Table 58 Global Needle-Free Injector Market, By Products, 2008 – 2015 ($Million)
Table 59 Global Transdermal Patch Technology, By Geography, 2008 – 2015 ($Million)
Table 60 Impact Analysis Of Key Market Dynamics
Table 61 Global Implantable Drug Delivery Technology Market, By Products, (2008 – 2015)
Table 62 Global Implantable Drug Delivery Technology Market, By Geography, 2008 – 2015 ($Million)
Table 63 Impact Analysis Of Key Market Dynamics
Table 64 Global Coronary Stents Market, By Geography, 2008 – 2015 ($Million)
Table 65 Global Implantable Infusion Pumps Market, By Geography, 2008 – 2015 ($Million)
Table 66 Global Ocular Implants & Others Market, By Geography, 2008 – 2015 ($Million)
Table 67 Global Liposomal Drug Delivery Market, By Geography, 2008 – 2015 ($Million)
Table 68 Impact Analysis Of Key Market Dynamics
Table 69 Global Pegylation Technology Market, By Geography, 2008 – 2015 ($Million)
Table 70 Impact Analysis Of Key Market Dynamics
Table 71 Revenue Analysis, 2008 – 2009
Table 72 Elan Total Revenues By Drug, 2008 – 2010
Table 73 Alkermes Total Revenues, By Drug, 2008 – 2010
Table 74 R&D Expenditure, 2008 – 2009
Table 75 Elan’S Pipeline Drugs
Table 76 Biovail’S Pipeline Drugs
Table 77 Alkermes’S Pipeline Drugs
Table 78 Nektar’S Pipeline Drugs
Table 79 Skye Pharma’S Pipeline Drugs
Table 80 Top Companies & Their Strategies
Table 81 Becton Dickinson – Total Revenues, By Segment ($Million)
Table 82 Baxter Biopharma Revenues, By Segment
Table 83 Ypsomed - Total Revenues, By Segment ($Million)
Table 84 Top 10 Drug Delivery Technologies Market, By Region, 2008 – 2015
Table 85 North American Top 10 Drug Delivery Technologies Market, By Segment
Table 86 European Top 10 Drug Delivery Technologies Market, By Segment
Table 87 Asian Top 10 Drug Delivery Technologies
Table 88 Rest Of The World Top 10 Drug Delivery Technologies Market
Table 89 Multiple Sclerosis Prevalence, By Geography, 2009
Table 90 Osteoporosis Prevalence, By Geography, 2009
Table 91 Diabetes Prevalence, By Geography, 2009
Table 92 Cancer Prevalence, By Geography, (2009)
Table 93 Rheumatoid Arthritis Prevalence, By Geography, (2009)
Table 94 Anemia Prevalence, By Geography, 2009
Table 95 Hepatitis-C Prevalence, By Geography, 2009
Table 96 Crohn’S Disease Prevalence, By Geography, 2009
Table 97 Psoriasis Prevalence, By Geography, 2009
Table 98 Total Revenues & R&D Expenditure
Table 99 Total Revenues, By Geography
Table 100 Total Revenues, 2006 – 2010
Table 101 Segment Specific Revenues ($Million)
Table 102 Total Revenues & R&D Expenditure ($Million)
Table 103 Total Revenues, By Geography
Table 104 Revenues, By Segments
Table 105 Total Revenues & Net Income ($Million)
Table 106 Total Revenues, 2007 – 2009
Table 107 Baxter Biopharma – Total Revenues & R&D Expenses ($Million)
Table 108 Baxter Biopharma – Total Revenues, By Geography ($Million)
Table 109 Baxter Biopharma – Total Revenues, By Segments ($Million)
Table 110 Baxter Biopharma – Total Revenues For Medication Delivery, By Segments ($Million)
Table 111 Becton Dickinson – Total Revenues & R&D Expenditure ($Million)
Table 112 Becton Dickinson – Total Revenues, By Geography ($Million)
Table 113 Becton Dickinson – Total Revenues, By Segments ($Million)
Table 114 Becton Dickinson – Total Revenues For Medical Surgical Systems, By Segments ($Million)
Table 115 Total Revenues & R&D Expenditure
Table 116 Revenues, By Segments ($Million)
Table 117 Total Revenues & R&D Expenditure ($Million)
Table 118 U.S Revenues Of Biovail, By Products ($Million)
Table 119 Total Product Revenues Of Biovail Pharmaceuticals Canada
Table 120 Total Revenues & R&D Expenditure
Table 121 Revenues, By Products
Table 122 Total Revenues & R&D Expenditure
Table 123 Total Revenues & R&D Expenditure ($Million)
Table 124 Product Sales, By Therapeutic Area
Table 125 Revenues & R&D Expenditure
Table 126 Total Revenues & R&D Expenditure
Table 127 Revenues, By Business Segments
Table 128 Revenues, By Products
Table 129 Revenues, By Geography ($Million)
Table 130 Total Revenues & Expenditure
Table 131 Total Revenues & R&D Expenditure
Table 132 Nektar – Total Revenues & R&D Expenses
Table 133 Nektar – Total Revenues, By Geography ($Million)
Table 134 Qlt – Total Revenues & R&D Expenses ($Million)
Table 135 Qlt – Total Revenues, By Geography ($Million)
Table 136 Total Revenues & R&D Expenses ($Million)
Table 137 Surmodics Inc. – Total Revenues & R&D Expenses ($Million)
Table 138 Surmodics Inc. – Total Revenues, By Geography ($Million)
Table 139 Surmodics Inc. – Total Revenues, By Segments ($Million)
Table 140 Total Revenues & R&D Expenditure
Table 141 Ypsomed - Total Revenues & R&D Expenses ($Million)
Table 142 Ypsomed - Total Revenues, By Segments ($Million)

List Of Figures

Figure 1 Revenue Analysis Of The Top 10 Drug Delivery Technologies
Figure 2 Top 10 Drug Delivery Technologies – Market Share
Figure 3 Evolution Of Drug Delivery Technology Industry
Figure 4 Role Of Drug Delivery Technologies In A Drug Life Cycle
Figure 5 Drug Delivery Technologies As Revenue Drivers
Figure 6 Drug Delivery Market Stakeholders
Figure 7 Impact Of Market Drivers & Restraints
Figure 8 Comparative Analysis Of Drug Delivery Technologies
Figure 9 Patent Analysis, By Segments, (2004 – 2009)
Figure 10 Patent Analysis, By Assignee, (2004 – 2009)
Figure 11 Common Reasons For Failure Of Drugs In Drug Discovery/ Development Process
Figure 12 Evolution Of Controlled Release Technologies
Figure 13 Controlled Release Vs Immediate Release
Figure 14 Targeted Therapy Types
Figure 15 Evolution Of Encapsulation Technologies
Figure 16 Encapsulation Applications In Different Modes Of Drug Delivery
Figure 17 Evolution Of Inhaler Technology
Figure 18 Factors Affecting Selection Of Injectable Device
Figure 19 Competitive Developments, 2007 – June 2010
Figure 20 Competitive Developments, By Segments, 2007 – June 2010
Figure 21 Revenue Analysis, 2008 – 2009
Figure 22 Controlled Release, Drug Formulation – Market Share
Figure 23 R&D Expenditure, 2008 – 2009
Figure 24 Injectable Drug Delivery Devices, Market Share
Figure 25 Top 10 Drug Delivery Technologies Market
Figure 26 Top 10 Drug Delivery Technologies Market – North America
Figure 27 Top 10 Drug Delivery Technologies Market – Europe
Figure 28 Top 10 Drug Delivery Technologies Market – Asia
Figure 29 Top 10 Drug Delivery Technologies Market – Row

Top 10 Drug Delivery Technologies Market To Grow Exponentially

The increasing demand for effective delivery of novel biopharmaceuticals is driving the growth of the global top 10 drug delivery technologies market. Patent expirations of drugs, need for faster drug development and greater drug approvals are further fuelling market growth. The global top 10 drug delivery technologies market is expected to grow from $43.8 billion in 2009 to $81.5 billion in 2015, at an estimated CAGR of 11% from 2010 to 2015. The time release technologies market commands the largest share around 19% of the overall top 10 drug delivery technologies market, owing to immense popularity of once-daily formulations.

Drug delivery technologies are revenue boosters for the pharmaceutical industry as they enhance drug life cycle in the market by extending patent rights, adding a competitive edge to the drug by enhancing their safety and efficacy. Further, expansion of the applications of non conventional modes of drug delivery such as pulmonary, nasal and transdermal in disease conditions other than respiratory and skin, especially in chronic disease conditions such as diabetes, CNS are also boosting the market. In addition, innovations such as microneedle transdermal patches and novel intelligent inhalers are also adding to the market growth. However, recent drug failures such as Exubera by Pfizer is a hindrance for the market.

Prominent industry participants include Elan, Biovail, Nektar and Alkermes. Pure drug delivery technology providers are gradually shifting towards specialty pharmaceuticals with focus on CNS and Cancer. Further, industry players are focusing on developing alternatives that are not only safe and effective but also are convenient in terms of drug administration and dosing regimen.

Currently, market players are focusing in the development and commercialization of new drugs through agreements and collaborations which therefore accounted for the highest share of the total competitive developments in the global top 10 drug delivery technologies market from 2007 to June 2010.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos